Fortrea sees growing early inclusion of China in global rare disease trials

• Global sponsors increasingly include China early in rare disease trials to accelerate recruitment and streamline development, according to Fortrea’s industry analysis.
• China has more than 20 million people affected by rare diseases, offering sponsors a broader recruitment pool.
• Participation in Phase I or Phase II programs may reduce additional study requirements later in development.
• Shorter regulatory reviews and lower operating costs than some Western markets can improve trial efficiency.
• Delaying China’s inclusion risks missed recruitment opportunities, greater operational complexity and weaker alignment across global development programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortrea Holdings Inc. published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.